Axitan’s intellectual property gains steam

Axitan’s FORC3® patent enters regional phase

Axitan’s patent application associated with its lead product FORC3®, with priority filing in Jan. 2019 (GB1901364.8) and PCT filing in Jan. 2020 (WO2020157519A1), have all now progressed into selected national and regional phases. Selected entries into the United States (US20220290114A1), European Union (EP3918061A1), Brazil (BR112021015059A2), and China (CN113677794A) reflect Axitan’s global ambitions and the markets it aims to develop. Axitan expects patent grant approvals in 2023.

The patent application makes a number of claims to protect Axitan’s novel FORC3® product, including relevant variations to the innovation. These include (1) the identification of several novel endolysin DNA sequences, (2) the expression of synergistic endolysins in Axitan’s proprietary microalgae strain, (3) enhancement of antimicrobial activities in the proprietary strain, and (4) the oral delivery of FORC3® to chickens for the management of specific pathogenic bacteria. Furthermore, claim language covering the expression of any other endolysin in microalgae for addressing Clostridium perfringens contaminations is also present.

Axitan intends to continue to build-out its intellectual property with future patent applications and know-how generated through the development of novel microalgae-based solutions that seek to displace the use of conventional antibiotics within animal agriculture.